Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.

Market Cap	$304.05M	P/E Ratio	N/A
52W High	$18.23	52W Low	$8.12
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	36.3%	52W Position	14.9%
Overall Score	39	Value Score	60
Quality Score	47	Technical Score	10

EPS Current Est	$-0.86	EPS Next Est	$0.1
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DCTH	$9.63	0.00%	292.77K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DCTH	$9.63	0%	292.77K
3
4
5
6

DCTH

DCTH

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Delcath Systems Inc. Data in Excel

Get Delcath Systems Inc. Data in Excel